The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy

The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: زهرا اسدزاده , بهزاد منصوری , توحید کاظمی , امیر علی مختارزاده , داریوش شانه بندی , نیما همت , افشین درخشانی , سحر صفائی , مرجان آقاجانی , سوزان نجفی , بهزاد برادران

کلمات کلیدی: CD133 siRNA Oxaliplatin Combination therapy Colorectal cancer

نشریه: 0 , 2021 , 137 , 2021

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله بهزاد برادران
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات ایمونولوژی
کد مقاله 75760
عنوان فارسی مقاله The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy
عنوان لاتین مقاله The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy
ناشر 14
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ خیر
عنوان نشریه (خارج از لیست فوق) Biomedicine & Pharmacotherapy
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Colorectal cancer (CRC) is considered one of the leading types of cancer in the world. CD133, as a cancer stem cell marker, has a pivotal role in the development of drug resistance, migration, and stemness properties of CRC cells. This study was designed to check the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in the HT-29 cell line. MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT- PCR and western blot were exploited, respectively. The results demonstrated that the silencing of CD133 could reduce the relative expression of this marker to about 0.00001 compared to the control group and reduce the protein level to 0.01. The ability of cell migration was tested by wound healing assay as well. Also, colony formation and sphere formation were conducted to assess the stemness properties in the combination group. Flow cytometry was conducted to investigate the apoptosis (15%), cell cycle (about 10% arresting in G0-G1 phase), and surface expression of CD133 in different groups (from 39.3% in the control group to 2.41 in the combination group). Finally, the expression of migration-, and stemness-associated genes were measured by qRT- PCR. We indicated that silencing of CD133 reduces the migration and stemness properties of colorectal cancerous cells. This suppression makes HT-29 cells more sensitive to Oxaliplatin and reduces the effective dose of this chemical drug. Therefore, the suppression of CD133 in combination with Oxaliplatin treatment might be a promising therapeutic approach in the treatment of colorectal cancer.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
زهرا اسدزادهاول
بهزاد منصوریدوم
توحید کاظمیچهارم
امیر علی مختارزادهپنجم
داریوش شانه بندیششم
نیما همتهفتم
افشین درخشانیهشتم
سحر صفائیدهم
مرجان آقاجانییازدهم
سوزان نجفیدوازدهم
بهزاد برادرانچهاردهم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
504-The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy.pdf1400/02/125892409دانلود